Thrivent Financial for Lutherans Has $1.11 Million Holdings in GSK plc (NYSE:GSK)

Thrivent Financial for Lutherans increased its stake in GSK plc (NYSE:GSK – Get Rating) by 3.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,627 shares of the pharmaceutical company’s stock after buying an additional 1,012 shares during the quarter. Thrivent Financial for Lutherans’ holdings in GSK were worth $1,111,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Glenview Trust Co lifted its holdings in GSK by 12.1% during the 4th quarter. Glenview Trust Co now owns 8,877 shares of the pharmaceutical company’s stock valued at $312,000 after purchasing an additional 960 shares during the last quarter. Keating Investment Counselors Inc. lifted its holdings in GSK by 40.2% during the 4th quarter. Keating Investment Counselors Inc. now owns 197,918 shares of the pharmaceutical company’s stock valued at $6,955,000 after purchasing an additional 56,742 shares during the last quarter. Blume Capital Management Inc. lifted its holdings in GSK by 65.8% during the 4th quarter. Blume Capital Management Inc. now owns 2,420 shares of the pharmaceutical company’s stock valued at $85,000 after purchasing an additional 960 shares during the last quarter. Equity Investment Corp lifted its holdings in GSK by 10.0% during the 4th quarter. Equity Investment Corp now owns 2,877,793 shares of the pharmaceutical company’s stock valued at $101,126,000 after purchasing an additional 261,161 shares during the last quarter. Finally, Stockman Wealth Management Inc. lifted its holdings in GSK by 3.2% during the 4th quarter. Stockman Wealth Management Inc. now owns 156,861 shares of the pharmaceutical company’s stock valued at $5,512,000 after purchasing an additional 4,871 shares during the last quarter. Institutional investors and hedge funds own 13.15% of the company’s stock.

GSK Stock Performance

GSK stock opened at $35.35 on Tuesday. GSK plc has a 12-month low of $28.47 and a 12-month high of $45.14. The company has a quick ratio of 0.69, a current ratio of 0.95 and a debt-to-equity ratio of 1.47. The business’s 50-day moving average price is $36.15 and its two-hundred day moving average price is $35.27. The stock has a market cap of $72.38 billion, a PE ratio of 4.27, a P/E/G ratio of 1.78 and a beta of 0.67.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 13th. Shareholders of record on Friday, May 19th will be given a $0.3475 dividend. This represents a $1.39 dividend on an annualized basis and a yield of 3.93%. The ex-dividend date is Thursday, May 18th. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s payout ratio is currently 16.43%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their target price on GSK from GBX 1,350 ($16.79) to GBX 1,400 ($17.41) in a report on Thursday, February 2nd. Deutsche Bank Aktiengesellschaft raised GSK from a “hold” rating to a “buy” rating in a report on Friday, March 17th. StockNews.com initiated coverage on GSK in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Berenberg Bank lifted their target price on GSK from GBX 1,580 ($19.65) to GBX 1,730 ($21.52) in a report on Friday, February 10th. Finally, The Goldman Sachs Group initiated coverage on GSK in a report on Sunday, February 26th. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK presently has an average rating of “Hold” and an average price target of $1,576.88.

GSK Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations, Research and Development, and Consumer Healthcare. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.